NovoMix 30 + Tablet treatment
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Latent Autoimmune Diabetes in Adults LADA
Conditions
Latent Autoimmune Diabetes in Adults LADA
Trial Timeline
Apr 1, 2007 → Apr 1, 2011
NCT ID
NCT00776607About NovoMix 30 + Tablet treatment
NovoMix 30 + Tablet treatment is a pre-clinical stage product being developed by Novo Nordisk for Latent Autoimmune Diabetes in Adults LADA. The current trial status is unknown. This product is registered under clinical trial identifier NCT00776607. Target conditions include Latent Autoimmune Diabetes in Adults LADA.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00776607 | Pre-clinical | UNKNOWN |
Competing Products
2 competing products in Latent Autoimmune Diabetes in Adults LADA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH) | Merck | Phase 1 | 33 |
| Rifapentine + Isoniazid | Sanofi | Phase 1/2 | 40 |